Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The ASCVD Risk Calculator estimates a patient's 10-year risk of a first atherosclerotic cardiovascular event (heart attack or stroke) using the 2013 ACC/AHA Pooled Cohort Equations. This replaced the Framingham Risk Score in US guidelines for determining statin therapy eligibility. The calculator uses age, sex, race, total and HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes, and smoking status. Risk thresholds guide statin therapy: <5% low, 5–7.5% borderline, 7.5–20% intermediate (moderate-intensity statin), ≥20% high (high-intensity statin).
Formula: Pooled Cohort Equations (2013 ACC/AHA) — race/sex-specific Cox proportional hazards model with ln-transformed coefficients.
Input age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes status, and smoking status.
The calculator applies race/sex-specific coefficients from the Pooled Cohort Equations to estimate the probability of a first ASCVD event (MI or stroke) within 10 years.
Compare the risk percentage to guideline thresholds: <5% low, 5–7.5% borderline, 7.5–20% intermediate, ≥20% high. Consider risk enhancers and CAC scoring for intermediate-risk patients.
Primary care physicians, cardiologists
The primary purpose of the ASCVD calculator is to guide the clinician-patient discussion about initiating statin therapy for primary prevention in adults aged 40–79.
Family medicine, internal medicine
Calculate ASCVD risk during annual wellness exams when lipid panels and blood pressure are available. Use the result to frame discussions about lifestyle and medications.
All clinicians, health educators
Provide patients with a concrete, personalized number to understand their cardiovascular risk. A '15% 10-year risk' is more tangible than abstract discussions of cholesterol levels.
Clinical researchers, quality officers
ASCVD risk is used in population health management to identify high-risk patients for outreach, in research as an inclusion/stratification variable, and in quality reporting.
Cardiologists, imaging centers
For intermediate-risk patients (7.5–20%), CAC scoring helps reclassify risk. A CAC of 0 may allow deferral of statins; CAC ≥100 strengthens the case for therapy.
All clinicians
2018 ACC/AHA guidelines emphasize a risk discussion before initiating statins. The ASCVD risk estimate is the foundation of that conversation, balanced against patient preferences.
The Pooled Cohort Equations estimate risk of a FIRST ASCVD event. Patients with established ASCVD (prior MI, stroke, PAD) already qualify for high-intensity statins regardless of calculated risk.
For patients at 5–20% risk, risk-enhancing factors (family history, LDL ≥160, CKD [assess with [eGFR Calculator](/tools/egfr-calculator)], inflammatory conditions, metabolic syndrome, elevated Lp(a)) favor statin therapy.
For intermediate-risk patients uncertain about statins, CAC scoring can help. CAC = 0 suggests deferral is reasonable; CAC 1–99 favors statins; CAC ≥100 or ≥75th percentile strongly favors therapy.
Studies show the Pooled Cohort Equations can overestimate risk by 20–50% in some contemporary populations, particularly higher-SES groups. Clinical judgment should supplement the number.
The equations were developed primarily in White and African American populations. South Asian patients have higher cardiovascular risk at lower traditional risk factor levels — consider this in discussions.
Patients with LDL ≥190 mg/dL have severe hypercholesterolemia and qualify for high-intensity statins without needing to calculate ASCVD risk.
Diabetic patients aged 40–75 qualify for at least moderate-intensity statin therapy. The ASCVD risk determines whether high-intensity (≥7.5% risk) or moderate-intensity (<7.5%) is indicated.
The calculated risk assumes no intervention. Statin therapy, blood pressure control, smoking cessation, and lifestyle changes (calculate your [BMI](/tools/bmi-calculator), track calories with [TDEE Calculator](/tools/tdee-calculator)) can significantly reduce actual risk below the baseline estimate.
The equations were developed using fasting lipid panels. Non-fasting values are acceptable for initial screening but may slightly affect accuracy.
If a patient quits smoking, loses significant weight, or has major blood pressure changes, recalculate ASCVD risk. The conversation about statins may change.
The ASCVD Risk Calculator implements the 2013 ACC/AHA Pooled Cohort Equations (Goff et al., Circulation 2014). It is incorporated into the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol as the recommended risk assessment tool for statin therapy decision-making in primary prevention. The equations were derived from ARIC, CARDIA, CHS, and Framingham cohorts.
Your 10-year ASCVD risk is expressed as a percentage representing the probability of experiencing a first atherosclerotic cardiovascular event (non-fatal myocardial infarction, coronary heart disease death, or fatal or non-fatal stroke) over the next 10 years. The risk is categorized into four tiers that guide clinical management: low risk (<5%) generally requires lifestyle modification only; borderline risk (5-7.5%) may warrant consideration of risk-enhancing factors; intermediate risk (7.5-20%) often warrants moderate-intensity statin therapy, especially if risk enhancers are present; and high risk (>=20%) generally warrants high-intensity statin therapy.
The calculated risk is a population-level estimate, not a guarantee of individual outcome. A 15% risk means that out of 100 people with your risk profile, approximately 15 would be expected to experience a cardiovascular event over 10 years. The remaining 85 would not. Risk factor modification through lifestyle changes, statin therapy, and blood pressure management can significantly reduce your actual risk below this baseline estimate.
For patients in the intermediate risk category (7.5-20%), the 2018 ACC/AHA guidelines suggest that coronary artery calcium (CAC) scoring can help refine the decision about statin therapy. A CAC score of zero may allow deferral of statin therapy, while a CAC score of 100 or higher (or >=75th percentile for age/sex) favors initiating statin therapy.
Use the ASCVD Risk Calculator for primary prevention risk assessment in adults aged 40-79 who do not already have established atherosclerotic cardiovascular disease. It is the recommended risk assessment tool in the 2018 ACC/AHA cholesterol guidelines and is intended to guide the clinician-patient risk discussion about initiating statin therapy. The calculator is most useful during routine preventive visits when lipid panels and blood pressure measurements are available.
The tool is particularly valuable for patients whose risk is not immediately obvious from a single risk factor alone. For example, a patient with mildly elevated cholesterol, mildly elevated blood pressure, and a family history of heart disease may have a higher combined risk than expected. Conversely, a patient with a single markedly elevated risk factor (e.g., LDL >190) already qualifies for high-intensity statin therapy regardless of the calculated risk score.
The Pooled Cohort Equations were derived from predominantly White and African American cohorts and may not accurately estimate risk in other racial and ethnic groups, including Hispanic, Asian, and South Asian populations. South Asian ancestry is considered a risk-enhancing factor because cardiovascular risk tends to be higher than what the equations predict for this group.
The equations have been shown to overestimate risk in some contemporary populations, particularly among higher socioeconomic status groups and populations with lower baseline cardiovascular event rates than the derivation cohorts. This overestimation means some patients may be classified as higher risk than their true risk, potentially leading to unnecessary statin initiation. CAC scoring can help reclassify these patients.
The calculator does not incorporate several important risk modifiers including family history of premature ASCVD, LDL-C level, triglycerides, inflammatory markers (hs-CRP), lipoprotein(a), ankle-brachial index, or metabolic syndrome. These risk-enhancing factors should be considered separately in the clinical decision-making process, especially for patients in the borderline or intermediate risk categories. The equations are also not applicable to patients with existing ASCVD, familial hypercholesterolemia, or LDL-C >=190 mg/dL, all of whom already qualify for statin therapy.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate your 10-year risk of cardiovascular disease using the Framingham Risk Score. Based on the landmark Framingham Heart Study data.
CardiologyCalculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.
CardiologyClassify heart failure severity using the New York Heart Association (NYHA) functional classification system. Classes I–IV based on physical activity limitations.
CardiologyCalculate LDL cholesterol from total cholesterol, HDL, and triglycerides using the Friedewald equation. Also reports non-HDL and total/HDL ratio.